Received: May 17, 2010
Accepted: July 24, 2010
Ref: Avasthi S. Vincristine: a new treatment option for Kasabach-Merritt Syndrome. Internet J Med Update. 2011 Jul;6(2):53-6.
VINCRISTINE: A NEW TREATMENT OPTION FOR KASABACH-MERRITT SYNDROME
Shalini Avasthi MD
Lecturer, Department of Pediatrics, Era,s Medical College, Lucknow, Uttar Pradesh, India
(Corresponding Author: Dr. Shalini Avasthi, Department of Pediatrics, Era,s Medical College, Lucknow, Uttar Pradesh, India; Email: firstname.lastname@example.org)
Kasabach-Merritt syndrome (KMS) is characterized by a rapidly enlarging hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption coagulopathy as a result of platelet and red blood cell trapping and activation of clotting system within the vasculature of hemangioma. This syndrome is shown to be associated with kaposiform hemangioendotheliomas or tufted hemangioma.
KEY WORDS: Kasabach-Merritt Syndrome; Microangiopathic hemolytic anemia; Thrombocytopenia; Consumption coagulopathy